Literature DB >> 3148594

Xenogenization of tumor cells by transfection with plasmid containing env gene of Friend leukemia virus.

C Sugiura1, T Itaya, N Kondoh, T Oikawa, N Kuzumaki, N Takeichi, M Hosokawa, H Kobayashi.   

Abstract

A rat hepatocellular carcinoma cell line (cKDH-8 cl-11) showed decreased tumorigenicity after transfection with an envelope gene derived from a Friend leukemia virus (FV-env gene). FV-env gene product was found by indirect immunofluorescence staining to be expressed on the cell surface of the FV-env gene-transfected cells. The FV-env-transfected cells (FV-env cKDH-8), however, grew well in X-irradiated immunosuppressed rats, indicating that the reduction in tumorigenicity of the transfected cells is based on immunological reaction in the host. The rats which rejected FV-env cKDH-8 cells showed resistance to rechallenge with the parent cKDH-8 cl-11 tumor cells. These results suggest that the FV-env gene product may elicit antitumor immunity against FV-env cKDH-8 cells in a host with a resultant reduction in the tumorigenicity of these cells.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3148594      PMCID： PMC5917664          DOI： 10.1111/j.1349-7006.1988.tb01553.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  11 in total

1.  Increased immunogenicity of low-antigenic rat tumors after superinfection with endogenous murine C-type virus in nude mice.

Authors:  N Kuzumaki; E M Fenyö; B C Giovanella; G Klein
Journal:  Int J Cancer       Date:  1978-01-15       Impact factor: 7.396

2.  Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice.

Authors:  P J Lachmann; K Sikora
Journal:  Nature       Date:  1978-02-02       Impact factor: 49.962

3.  Immunization of mice against Ehrlich ascites tumour using a hamster-Ehrlich ascites tumour hybrid cell line.

Authors:  J F Watkins; L Chen
Journal:  Nature       Date:  1969-09-06       Impact factor: 49.962

4.  Nucleotide sequence of the envelope gene of Friend murine leukemia virus.

Authors:  W Koch; G Hunsmann; R Friedrich
Journal:  J Virol       Date:  1983-01       Impact factor: 5.103

5.  Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells.

Authors:  M Hosokawa; T Okayasu; K Ikeda; H Katoh; Y Suzuki; H Kobayashi
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

6.  Assay of transforming activity of tumor virus DNA.

Authors:  A J van der Eb; F L Graham
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

7.  Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo.

Authors:  F Plata; P Langlade-Demoyen; J P Abastado; T Berbar; P Kourilsky
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

8.  Xenogenization of a mouse lung carcinoma (3LL) by transfection with an allogeneic class I major histocompatibility complex gene (H-2Ld).

Authors:  T Itaya; S Yamagiwa; F Okada; T Oikawa; N Kuzumaki; N Takeichi; M Hosokawa; H Kobayashi
Journal:  Cancer Res       Date:  1987-06-15       Impact factor: 12.701

9.  Immune response genes control T killer cell response against Moloney tumor antigen cytolysis regulating reactions against the best available H-2 + viral antigen association.

Authors:  E Gomard; Y Hénin; M J Colombani; J P Lévy
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

10.  Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase.

Authors:  G A Currie; K D Bagshawe
Journal:  Br J Cancer       Date:  1969-03       Impact factor: 7.640
View more
  8 in total

1.  Transfection of the Newcastle disease virus hemagglutinin-neuraminidase gene into murine myeloma cells for induction of host-versus-tumor immune response.

Authors:  N V Risinskaya; O V Vasilenko; K V Fegeding; A B Sudarikov
Journal:  Dokl Biochem Biophys       Date:  2001 May-Jun       Impact factor: 0.788

2.  Membrane-bound complement regulatory activity is decreased on vaccinia virus-infected cells.

Authors:  L Baranyi; N Okada; K Baranji; H Takizawa; H Okada
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

3.  Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma.

Authors:  L Baranyi; K Baranji; H Takizawa; N Okada; H Okada
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

4.  Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin.

Authors:  L Yuan; Y Kuramitsu; Y Li; M Kobayashi; M Hosokawa
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

5.  Immunotherapy of malignancy by in vivo gene transfer into tumors.

Authors:  G E Plautz; Z Y Yang; B Y Wu; X Gao; L Huang; G J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

6.  The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma.

Authors:  S J Hollingsworth; D Darling; J Gäken; W Hirst; P Patel; M Kuiper; P Towner; S Humphreys; F Farzaneh; G J Mufti
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

7.  Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour.

Authors:  P M Patel; C L Flemming; S J Russell; I A McKay; K A MacLennan; G M Box; S A Eccles; M K Collins
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640

8.  Progression of a weakly tumorigenic mouse fibrosarcoma at the site of early phase of inflammation caused by plastic plates.

Authors:  F Okada; M Hosokawa; J Hamada; J Hasegawa; M Mizutani; N Takeichi; H Kobayashi
Journal:  Jpn J Cancer Res       Date:  1993-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.